



Formulary 1 Updates April 9, 2025

The following drug products were reviewed and acted upon by the CDPHP Pharmacy and Therapeutics Committee for The Formulary 1.

ACA Covered under the Affordable Healthcare Act-no member cost share

PA Prior authorization required

PD Preventive Drug

QL Quantity Limits Apply

SP Restricted to ConnectRx or CVS Caremark Specialty Pharmacy

ST Step Therapy

Drug	Previous Coverage	Coverage
Alhemo® (concizumab-mtci) subcutaneous injection	New to market	Tier 3, PA (Medical benefit, PA)
Alyftrek™ (vanzacaftor/tezacaftor/deutivacaftor) oral tablets	New to market	Not covered
Bizengri® (zenocutuzunab-zbco) intravenous infusion	New to market	Medical benefit, PA
Crenessity™ (crinecerfont) oral tablets	New to market	Tier 3, PA, QL
Datroway® (datopotamab deruxtecan-dlnk) intravenous infusion	New to market	Medical benefit, PA
Journavx® (suzetrigine) oral tablets	New to market	Tier 3, PA, QL
Kebilidi™ (eladocagene exuparvovec-tneq) Intraputaminal	New to market	Medical benefit, PA
Niktimvo™ (axatilimab-csfr) intravenous infusion	New to market	Medical benefit, PA
Tryngolza (olezarsen) Subcutaneous Injection	New to market	Tier 3, PA, QL
WellFola oral tablets (multi vitamin dietary supplement)	Tier 3	Not covered for new utilizers. Current utilizers grandfathered until renewal
Xromi oral solution (hydroxyurea)	New to market	Tier 3, PA, QL